NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Descrição da marca
The mark consists of the letters "TG" in grey and the word "thrombogenics" in red with a grey vertical line separating the literal elements of the mark.
Titulares
Representantes
Thomas J. Mango Cantor Colburn LLP
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical preparations and substances for use in the manufacture of pharmaceuticals
Classe 5
Pharmaceutical preparations for treatment of diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; veterinary preparations for treatment of diseases and disorders in mammalians, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; sanitary preparations for medical purposes; dietetic foods adapted for medical use, food for babies; medical plasters; material for stopping teeth, dental wax; disinfectants for medical instruments, for hygienic purposes, and for use in medical surgery procedures; preparations for destroying vermin; fungicides, herbicides; biopharmaceutical preparations, namely, anticoagulants, anti angiogenic drugs, anticancer drugs, cardiovascular drugs, protease enzymes, protease inhibitors, antibodies, plasmins, truncated plasmins, microplasmins, plasminogens, truncated plasminogens, microplasminogens, plasminogen activators, staphylokinases for the treatment diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; diagnostic medical reagents, chemicals and biological materials, namely, antigen and diagnostic kits consisting primarily of monoclonal and/or polyclonal antibodies, buffers, and reagents for medical laboratory use in disease testing
Classe 42
Scientific and technological services, namely, scientific research and design of new products in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention, and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; industrial analysis and product research services in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; pharmaceutical, biopharmaceutical, medical, biomedical, biological, biochemical, toxicological and clinical research and product development of diagnostic tests and kits, biopharmaceutical preparations and drugs, and medicines; biopharmaceutical product evaluation; biological, biochemical, pharmaceutical, medical, toxicological and clinical research, scientific research for medical purposes in the treatment of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer diseases and disorders; development services in the field of new biopharmaceutical drugs, preparations and medicines for ophthalmic, vascular and cancer pathologies
Classe 44
Medical services; veterinary services; medical, veterinary and pharmaceutical advisory and consultancy services; medical services, namely, therapeutic, prognostic and diagnostic testing services
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
NEW REPRESENTATIVE AT IB RECEIVED
08/01/2026
TOTAL INVALIDATION PROCESSED BY THE IB
11/04/2023
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
01/03/2023
INVALIDATION PROCESSED
01/03/2023
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
13/01/2023
CANCELLED SECTION 71
13/05/2022
INTERNATIONAL REGISTRATION RENEWED
17/12/2020
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
01/11/2020
CHANGE OF NAME/ADDRESS REC'D FROM IB
13/06/2019
PARTIAL INVALIDATION PROCESSED BY THE IB
08/03/2019
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
26/01/2019
INVALIDATION PROCESSED
26/01/2019
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
11/01/2019
NEW REPRESENTATIVE AT IB RECEIVED
28/09/2018
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
11/05/2018
REGISTERED - PARTIAL SEC 71 ACCEPTED
11/05/2018
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/05/2018
TEAS SECTION 71 RECEIVED
01/05/2018
FINAL DECISION TRANSACTION PROCESSED BY IB
28/07/2012
FINAL DISPOSITION NOTICE SENT TO IB
08/06/2012
FINAL DISPOSITION PROCESSED
08/06/2012
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/02/2012
REGISTERED-PRINCIPAL REGISTER
01/11/2011
PUBLISHED FOR OPPOSITION
16/08/2011
NOTICE OF PUBLICATION
27/07/2011
LAW OFFICE PUBLICATION REVIEW COMPLETED
13/07/2011
ASSIGNED TO LIE
12/07/2011
APPROVED FOR PUB - PRINCIPAL REGISTER
18/06/2011
TEAS/EMAIL CORRESPONDENCE ENTERED
17/06/2011
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/06/2011
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/06/2011
REFUSAL PROCESSED BY IB
09/04/2011
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/03/2011
REFUSAL PROCESSED BY MPU
22/03/2011
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/03/2011
NON-FINAL ACTION WRITTEN
18/03/2011
APPLICATION FILING RECEIPT MAILED
12/03/2011
ASSIGNED TO EXAMINER
08/03/2011
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/03/2011
LIMITATION FROM ORIGINAL APPLICATION ENTERED
04/03/2011
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/03/2011
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.